Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
New ticker symbol (Nasdaq: QNCX) to initiate trading on
Additionally, the company’s ticker symbol on the Nasdaq Global Select Market is expected change to “QNCX” effective at the open of market trading on
Quince Therapeutics also plans to launch its new corporate website and social media presence on Twitter and LinkedIn on
Forward-Looking Statements
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast,” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our anticipated corporate name change and related timing. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in Cortexyme’s Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005263/en/
Cortexyme Contact:
Vice President,
ir@cortexyme.com
Source: